LAVA Therapeutics N.V.

0.96
0.02 (1.59%)
At close: Feb 07, 2025, 3:59 PM
1.00
4.16%
After-hours Feb 07, 2025, 04:00 PM EST
undefined%
Bid 0.96
Market Cap 25.24M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.01
PE Ratio (ttm) -0.95
Forward PE n/a
Analyst Hold
Ask 1
Volume 9,109
Avg. Volume (20D) 105,615
Open 0.97
Previous Close 0.94
Day's Range 0.96 - 0.98
52-Week Range 0.88 - 6.47
Beta undefined

About LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for b...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 37
Stock Exchange NASDAQ
Ticker Symbol LVTX

Analyst Forecast

According to 3 analyst ratings, the average rating for LVTX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 108.31% from the latest price.

Buy 33.33%
Hold 66.67%
Sell 0.00%
Stock Forecasts

Next Earnings Release

LAVA Therapeutics N.V. is scheduled to release its earnings on Mar 19, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-23.56%
LAVA Therapeutics shares are trading lower after t... Unlock content with Pro Subscription